<DOC>
	<DOC>NCT01688843</DOC>
	<brief_summary>The objective of this study is to gather data to establish the safety, performance and effectiveness of the INGEVITY pace/ sense leads.</brief_summary>
	<brief_title>Safety and Performance Study of the INGEVITY Lead</brief_title>
	<detailed_description />
	<mesh_term>Bradycardia</mesh_term>
	<mesh_term>Sick Sinus Syndrome</mesh_term>
	<criteria>Subject is willing and capable of providing informed consent Subject has a Class I or II indication for implantation of a single(VVI (R) only) or dual chamber pacemaker or a CRTP system according to the ACC/AHA/HRS, or ESC guidelines Subject is willing and capable of participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol Subject is age 18 or above, or of legal age to give informed consent specific to state and national law Subject has or has had any pacing or ICD system implants Subject has a sensitivity to dexamethasone acetate (DXA) Subject has a mechanical tricuspid heart valve Subject is enrolled in any other concurrent study, with the exception of local mandatory governmental registries and observational studies/registries Subjects with documented permanent or persistent AF where the physician intends to implant dual chamber pulse generator (single chamber VVIR pulse generators in these subjects is acceptable) Subject is currently on the active heart transplant list Subject has documented life expectancy of less than 12 months Women of childbearing potential who are or might be pregnant at the time of study enrollment or INGEVITY Lead implant Subjects currently requiring dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bradycardia</keyword>
	<keyword>sinus node dysfunction</keyword>
</DOC>